Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 4/20 | 0.42 |
| ▸ | ACE | P12821 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18829369 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPACE | |
| SCHEMBL1759496 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPACE | |
| SCHEMBL15804513 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPACE | |
| SCHEMBL12684327 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPACE | |
| SCHEMBL14733315 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPACE | |
| SCHEMBL18300694 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPACE | |
| SCHEMBL18300764 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPACE | |
| SCHEMBL1336739 | 0.97 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPACE | |
| SCHEMBL8337646 | 0.97 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPACE | |
| SCHEMBL14053968 | 0.97 | CHRM2 (0.45) | CHRM2CHRM1CHRM3PREPACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | INSMED INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4561565-A2 | NOVEL DPP1 INHIBITORS AND USES THEREOF | Insmed Incorporated (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024182382-A1 | 4,5-FUSED BICYCLIC PYRROLIDINE AND 4,5-FUSED BICYCLIC PYRROLIDINONE COMPOUNDS | CYTEIR THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240083888-A1 | SMALL MOLECULE INHIBITOR FOR CATHEPSIN C AND MEDICINAL USE THEREOF | REISTONE BIOPHARMA COMPANY LIMITED (CN) | 2024-03-14 | — | — | US | disclosed |
| WO-2024026433-A2 | NOVEL DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-3533797-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-20 | — | — | EP | disclosed |
| EP-4257588-A1 | SMALL MOLECULE INHIBITOR OF CATHEPSIN C AND MEDICINAL USE THEREOF | Reistone Biopharma Company Limited (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20110092415-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092415-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-04-21 | — | — | US | disclosed |
| WO-2010120935-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| US-5068242-A | PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE FOR PSYCHOTROPIC ACTION | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-11-26 | — | — | US | disclosed |
| US-5043346-A | Amino acid esters, pharmaceuticals containing them, and the use thereof in learning disorders | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-08-27 | — | — | US | disclosed |
| US-4999370-A | ANXIOLYTIC AGENTS, INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME, NOOTROPIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-03-12 | — | — | US | disclosed |
| US-4983623-A | Prolyl endopeptidase inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CHRM2 4875/4885CHRM1 4854/4885CHRM3 4792/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CHRM2 4875/4885CHRM1 4854/4885CHRM3 4792/4885 |
| US-20110092415-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CHRM2 4875/4885CHRM1 4854/4885CHRM3 4792/4885 |
| US-20240083888-A1 | SMALL MOLECULE INHIBITOR FOR CATHEPSIN C AND MEDICINAL USE THEREOF | CTSF, CTSV, CTSB | CHRM2 3664/4885CHRM1 3867/4885CHRM3 2857/4885 |
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | DPP4, DPP3, DPP7 | CHRM2 195/4885CHRM1 130/4885CHRM3 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.